Wonderful Gem! I'm in with 1,000 shares. Currently underwater a tiny bit, but what can you expect right now? Until we get some decent news or updates, we'll get some churning and short players. ARNA is currently the wallstreet underdog.
I hope that the July 15 FDA panel delivers bad news to VVUS concerning Qnexa... They're using a generic drug combo and exploiting an anticonvuslant to achieve appetite suppression. Don't like it, and if the FDA doesn't like it as well, the game will change for ARNA!
I'm currently stuck on the question: What is the market need for these obesity drugs? That's a really generic question, for we all know that the metabolic drug market needs some good candidates to address the increasingly overweight. Will the FDA want to approve 1 drug, 2 drugs, or all 3?
Remember, key to a good drug: SAFETY >>> EFFICACY. Safety will allow Lorcaserin to be prescribed as a first line drug, and to be prescribed chronically. It works, but just not as well as Qnexa (according to the studies). Wallstreet just wants dazzled with efficacy and results, but physicians want more than just superfical glam. Ok it works well, but how safe is Qnexa? Fingers crossed that this one is the winner.
Good luck.
News 
Market Data 
Discover 
AI
